CSIMarket


Organogenesis Holdings Inc   (ORGO)
Other Ticker:  
 


 

Organogenesis Holdings Inc

ORGO's Financial Statements and Analysis



Organogenesis Holdings Inc reported in the third quarter of 2023 net earnings per share of $0.02 an increase by 0 % year on year from $0.00 and decline of -50 % from $0.04 earned in II. Quarter (Jun 30 2023).


third quarter of 2023
Earnings Per Share Revenues
$ 0.02 $  109 Mill
$+0.02     $-8M     -7.13 %



Organogenesis Holdings Inc 's Revenue fell by -7.13 % in third quarter of 2023 (Sep 30 2023) year on year, to $109 million and declined by -7.49 % sequentially.


Organogenesis Holdings Inc is Expected to report next financial results on February 29, 2024.

More on ORGO's Income Statement



Organogenesis Holdings Inc 's net income of $3.167 million in the third quarter of 2023 increased by 1373.02 % from net earnings of $0.215 million achieved in III. Quarter a year ago.

Sequentially net earnings fell by -40.43 % from net income of $5.316 million realized in previous quarter.

More on ORGO's Growth

Organogenesis Holdings Inc Inventories
Inventories grew by 13.05 % to $28 million from III. Quarter a year ago, sequentially inventories rose by 10.02 %. ORGO's Cash flow In the third quarter of 2023 company's net cash flow was $9 million, capital expenditures grew by -10.402-42.52%, to $-6 millions compare to same quarter a year ago

More on ORGO's Cash flow Statement


Organogenesis Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Organogenesis Holdings Inc earned $ 0.21 cash per share, on a free-cash flow basis 234.05 % of net earning per share.

Book value grew by 1.79 % sequentially to $2.08 per share, 152.71% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 1.73 per share from $ 1.68.

Company issued 0.35 million shares or 0.26 % in Sep 30 2023.
Interest Coverage Ratio was 12.62. Debt Coverage Ratio was 0.31.

More on ORGO's Dividends

 Market Capitalization (Millions) 466
 Shares Outstanding (Millions) 133
 Total Debt (Millions $) 68
 Revenue (TTM) (Millions $) 448
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) -32
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 896




Organogenesis Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Organogenesis Holdings Inc had $ 0.21 cash flow per share, on a free-cash flow basis 234.05 % of net earning per share.

Book value grew by 1.79 % sequentially to $2.08 per share, 152.71% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 1.73 per share from $ 1.68.

Company issued 0.35 million shares or 0.26 % in Sep 30 2023.
Interest Coverage Ratio was 12.62. Debt Coverage Ratio was 0.31.

More on ORGO's Balance Sheets

 Market Capitalization (Millions) 466
 Shares Outstanding (Millions) 133
 Total Debt (Millions $) 68
 Revenue (TTM) (Millions $) 448
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) -32
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 896
   


  News about Organogenesis Holdings Inc Earnings

Organogenesis Holdings Inc Displays Consistent Earnings per Share in Q3 2023 Earnings Season



Organogenesis Holdings Inc has experienced significant stock gains in recent months. However, a closer look at its financial results for the third quarter of the 2023 earnings season reveals a mixed picture. While income per share remained stable, profit and revenue experienced substantial declines. This article aims to interpret the impact of these financial results on Organogenesis Holdings Inc going forward.
1. Stock Gain:
Over the last five trading days, the stock of Organogenesis Holdings Inc has gained an impressive 16.1%. Furthermore, the stock has surged by a staggering 44.23% over the past 90 days. Currently trading on NASDAQ, the stock is performing exceptionally well, trading 34%...

Organogenesis Holdings Inc. Reports Decline in Revenue, but Surpasses EPS Expectations

Organogenesis Holdings Inc., a leading company in the Major Pharmaceutical Preparations sector, recently reported its financial results for the April to June 30, 2023 span. The earnings per share (EPS) for this period saw a significant decline of -42.86%, dropping to $0.04 per share compared to $0.07 per share in the same period the previous year. However, it is worth noting that the EPS turned positive from -$0.02 per share in the prior reporting season.
The revenue for Organogenesis Holdings Inc. also experienced a decrease of -3.365%, falling to $117.32 million from $121.40 million in the same reporting season a year prior. On a sequential basis, the revenue showed growth, advancing by 8.987% from $10...

Organogenesis Holdings Inc Faces Mounting Deficit Amid Challenging First Quarter of 2023

Organogenesis Holdings Inc is a biotech company specializing in regenerative medicine. However, their recent financial reports suggest that their ability to collect accounts receivable has been sequentially worsening, with their average receivable collection period increasing to 72 days in the March 2023 quarter, compared to 71 days in the previous quarter. This indicates a challenging and deteriorating business climate for the Major Pharmaceutical Preparations industry, which Organogenesis Holdings Inc is a part of.
Despite the overall decline in Organogenesis Holdings Inc's receivable turnover ratio, their total ranking has improved to 271 in the current quarter from the fourth quarter of 2022. When co...


Date modified: 2023-12-16T12:33:13+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com